InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

enGene Therapeutics Inc.

ENGN Clue Score29
Canada (Federal Level) Fiscal year ends October CIK 0001980845
$1.73 -2.81% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.73 −91.35% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 1 Nov 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2022Operating income−19.4Net income−24.5EPS, diluted44.30Fiscal year 2023Operating income−26.1Net income−99.9EPS, diluted151.22Fiscal year 2024Operating income−62.3Net income−55.1EPS, diluted1.46Fiscal year 2025Operating income−123.2Net income−117.3EPS, diluted2.29
FY2022FY2023FY2024FY2025
Operating income −19.4 −26.1 −62.3 −123.2
Net income −24.5 −99.9 −55.1 −117.3
Growth
EPS, diluted 44.30 151.22 1.46 2.29

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−17.6Capital expenditure−0.2Free cash flow−17.7Fiscal year 2023Operating cash flow−24.7Capital expenditure−0.3Free cash flow−25.1Dividends paid0.0Fiscal year 2024Operating cash flow−48.3Capital expenditure−0.9Free cash flow−49.2Fiscal year 2025Operating cash flow−99.2Capital expenditure−1.5Free cash flow−100.7
FY2022FY2023FY2024FY2025
Operating cash flow −17.6 −24.7 −48.3 −99.2
Capital expenditure −0.2 −0.3 −0.9 −1.5
Free cash flow −17.7 −25.1 −49.2 −100.7
Growth
Dividends paid n/a 0.0 n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash20.4Shareholders’ equity−76.6Fiscal year 2023Cash81.5Shareholders’ equity72.5Fiscal year 2024Cash173.0Shareholders’ equity272.6Fiscal year 2025Cash50.2Shareholders’ equity167.7
FY2022FY2023FY2024FY2025
Cash 20.4 81.5 173.0 50.2
Shareholders’ equity −76.6 72.5 272.6 167.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending October, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Oct 2022 FY2023 31 Oct 2023 FY2024 31 Oct 2024 FY2025 31 Oct 2025
Returns
n/a −137.8% −20.2% −69.9%
−102.3% −114.9% −17.7% −53.0%
Balance and payout
198.3% 16.6% 12.4% 24.3%